Seto T, Azuma K, Yamanaka T, et al. - In this randomized phase III study of continuation maintenance bevacizumab with or without pemetrexed, experts intend to assess the effectiveness and safety of bevacizumab with or without pemetrexed as continuation maintenance therapy following carboplatin, pemetrexed, and bevacizumab induction therapy. Within September 2010 and September 2015, 907 individuals underwent induction therapy. Of those, 599 were randomly selected as well as 298 received pemetrexed plus bevacizumab, and 301 received bevacizumab. Findings suggest that in terms of the primary endpoint of OS, no statistically notable advantage was seen, however, progression-free survival in all individuals population and OS in people with wild-type EGFR was prolonged with the addition of pemetrexed to bevacizumab maintenance therapy.